DE69032833D1 - Diagnose und behandlung von insulinabhängigem diabetes mellitus - Google Patents

Diagnose und behandlung von insulinabhängigem diabetes mellitus

Info

Publication number
DE69032833D1
DE69032833D1 DE69032833T DE69032833T DE69032833D1 DE 69032833 D1 DE69032833 D1 DE 69032833D1 DE 69032833 T DE69032833 T DE 69032833T DE 69032833 T DE69032833 T DE 69032833T DE 69032833 D1 DE69032833 D1 DE 69032833D1
Authority
DE
Germany
Prior art keywords
treatment
diabetes mellitus
dependent diabetes
insulin
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69032833T
Other languages
English (en)
Other versions
DE69032833T2 (de
Inventor
Irun R Cohen
Dana Elias
Doron Markovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69032833D1 publication Critical patent/DE69032833D1/de
Application granted granted Critical
Publication of DE69032833T2 publication Critical patent/DE69032833T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/965—Chemistry: molecular biology and microbiology involving idiotype or anti-idiotype antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
DE69032833T 1989-03-14 1990-03-14 Diagnose und behandlung von insulinabhängigem diabetes mellitus Expired - Lifetime DE69032833T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32286489A 1989-03-14 1989-03-14
US07/371,249 US5114844A (en) 1989-03-14 1989-06-26 Diagnosis and treatment of insulin dependent diabetes mellitus
PCT/US1990/001397 WO1990010449A1 (en) 1989-03-14 1990-03-14 Diagnosis and treatment of insulin dependent diabetes mellitus

Publications (2)

Publication Number Publication Date
DE69032833D1 true DE69032833D1 (de) 1999-01-28
DE69032833T2 DE69032833T2 (de) 1999-05-12

Family

ID=26983648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69032833T Expired - Lifetime DE69032833T2 (de) 1989-03-14 1990-03-14 Diagnose und behandlung von insulinabhängigem diabetes mellitus

Country Status (10)

Country Link
US (2) US5114844A (de)
EP (1) EP0417271B1 (de)
JP (3) JP3165148B2 (de)
AT (1) ATE174689T1 (de)
AU (1) AU639456B2 (de)
CA (1) CA2029861C (de)
DE (1) DE69032833T2 (de)
FI (1) FI103976B1 (de)
NO (1) NO300594B1 (de)
WO (1) WO1990010449A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
US5780034A (en) * 1989-03-14 1998-07-14 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
ES2223039T3 (es) 1990-09-07 2005-02-16 The Regents Of The University Of California Metodos para la diagnosis y tratamiento de diabetes.
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
CA2096975C (en) * 1990-11-26 2003-04-22 Carl Wu Cell stress transcriptional factors
US5767240A (en) * 1991-04-22 1998-06-16 The United States Of America As Represented By The Department Of Health And Human Services Activity-dependent neurotrophic factor
US6174862B1 (en) 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
EP0585356A1 (de) * 1991-05-15 1994-03-09 Zymogenetics, Inc. Klonierung und expression des humanen glutamiksaeuredekarboylase-autoantigens aus dem inselorgan
WO1993009141A1 (en) * 1991-11-01 1993-05-13 Joslin Diabetes Center Antigen associated with type i diabetes mellitus
AT398495B (de) * 1992-06-09 1994-12-27 Wick Georg Dr Diagnose oder vorhersage von atherosklerose
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003478A1 (en) * 1992-07-31 1994-02-17 Immulogic Pharmaceutical Corporation Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
US5872094A (en) * 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7008790B1 (en) 1993-08-12 2006-03-07 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
CN1103781C (zh) 1993-11-23 2003-03-26 加利福尼亚大学 丰富的细胞外产物和其生产与使用方法
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US5863742A (en) * 1994-03-10 1999-01-26 Chiron Diagnostics Corporation Inhibition of protease activity of human whole blood cell lysates
PT751957E (pt) * 1994-03-21 2004-07-30 Univ Utrecht Fragmentos peptidicos de proteinas de stress microbianas e composicao farmaceutica a base destes fragmentos para o tratamento e a prevencao de doencas inflamatorias
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6509165B1 (en) 1994-07-08 2003-01-21 Trustees Of Dartmouth College Detection methods for type I diabetes
EP0788512B1 (de) * 1994-07-08 1999-03-24 The Trustees Of Dartmouth College Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
WO1996005223A1 (en) * 1994-08-12 1996-02-22 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
GB9419553D0 (en) * 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
DK0820303T3 (da) * 1994-12-21 2003-10-06 Yeda Res & Dev p277 peptidanaloger og farmaceutiske sammensætninger, der omfatter dem, til behandling eller diagnosticering af diabetes
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US20030190323A1 (en) * 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
EP1047451A1 (de) * 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Verwendung von hitzeshockproteinen zur verabreichung von einheiten in zellen
ATE327259T1 (de) * 1997-08-05 2006-06-15 Stressgen Biotechnologies Corp Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
WO1999037315A1 (en) * 1998-01-27 1999-07-29 Bai Jane Pei Fan Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same
US8158125B2 (en) * 1998-11-05 2012-04-17 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases
US7488476B2 (en) * 1998-11-05 2009-02-10 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases
JP4717213B2 (ja) * 1998-11-05 2011-07-06 ハダシット、メディカル、リサーチ、サーヴィセズ、アンド、デヴェロップメント、リミテッド 新規なアミノ酸配列、そのアミノ酸配列をコードするｄｎａ、かかる配列に向けられた抗体およびその種々の使用
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US6495347B1 (en) 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
IL150113A0 (en) * 1999-12-15 2002-12-01 Peptor Ltd Fragments and antagonists of heat shock protein 60
ATE438408T1 (de) * 2000-01-14 2009-08-15 Whitehead Biomedical Inst Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
PT1296711E (pt) * 2000-06-26 2006-08-31 Stressgen Biotechnologies Corp E7 de vph para o tratamento do virus do papiloma humano
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
WO2002062959A2 (en) * 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
ES2526822T3 (es) 2002-01-31 2015-01-15 Andromeda Bio Tech Ltd. Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2005072056A2 (en) * 2004-01-28 2005-08-11 Develogen Israel Ltd. Hsp therapy in conjunction with a low antigenicity diet
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
ZA200707970B (en) 2005-03-14 2008-11-26 Yeda Res & Dev Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
EP1924293A4 (de) 2005-08-06 2008-12-24 Qinghua Wang Zusammensetzung und verfahren zur prävention und behandlung von diabetes typ i
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
DE102006019127A1 (de) * 2006-04-25 2007-10-31 Carl Zeiss Meditec Ag Multiwellenlängen-Lasersystem und Verfahren für ophthalmologische Anwendungen
WO2009090650A2 (en) 2008-01-16 2009-07-23 Ben-Gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
US20150011471A1 (en) 2012-03-01 2015-01-08 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
US20150018271A1 (en) 2012-03-01 2015-01-15 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
EP3090064B1 (de) 2013-12-31 2019-11-13 Yeda Research and Development Co. Ltd. Diagnose von systemischem lupus erythematodes mit hilfe von oligonukleotid-antigenen
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
KR101843000B1 (ko) * 2016-12-07 2018-03-28 주식회사 에프앤디파트너스 피부 트러블별 미용 또는 치료 기능을 제공하는 개인 맞춤형 기능성 팩 및 그의 사용 방법
KR102292635B1 (ko) 2019-07-26 2021-08-23 (의)삼성의료재단 마스크 팩

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
CA1320907C (en) * 1986-09-23 1993-08-03 Irun Robert Cohen Cell membrane proteins, compositions containing them and procedure for their preparation
US4952395A (en) * 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
EP0417271A4 (en) 1992-09-09
US5114844A (en) 1992-05-19
US5671848A (en) 1997-09-30
JP3203323B2 (ja) 2001-08-27
EP0417271A1 (de) 1991-03-20
FI905614A0 (fi) 1990-11-13
ATE174689T1 (de) 1999-01-15
JP2001010962A (ja) 2001-01-16
JP3165148B2 (ja) 2001-05-14
CA2029861A1 (en) 1990-09-15
DE69032833T2 (de) 1999-05-12
AU639456B2 (en) 1993-07-29
WO1990010449A1 (en) 1990-09-20
FI103976B (fi) 1999-10-29
NO300594B1 (no) 1997-06-23
JP2000055916A (ja) 2000-02-25
NO904919D0 (no) 1990-11-13
EP0417271B1 (de) 1998-12-16
NO904919L (no) 1991-01-14
AU5546790A (en) 1990-10-09
JPH04502920A (ja) 1992-05-28
FI103976B1 (fi) 1999-10-29
CA2029861C (en) 2001-01-16

Similar Documents

Publication Publication Date Title
ATE174689T1 (de) Diagnose und behandlung von insulinabhängigem diabetes mellitus
Rehfeld et al. Gel filtration studies on immunoreactive gastrin in serum from Zollinger-Ellison patients
Paull et al. Melittin: an allergen of honeybee venom
Duthie et al. A polypeptide responsible for some of the phenomena of acute inflammation
Levine et al. Studies on the immunological mechanisms of penicillin allergy: II. Antigenic specificities of allergic wheal-and-flare skin responses in patients with histories of penicillin allergy
GR3022287T3 (en) Detection of neurological disease or dysfunction
RU94046284A (ru) Способ обнаружения антител, способ с-крекинга компонентов крови, набор для обнаружения антител к hcv
ZA872166B (en) Synthetic htlv-iii peptides,compositions and uses thereof
Till et al. Activation of complement by radiographic contrast media: generation of chemotactic and anaphylatoxin activities
Harboe et al. Immunochemical properties of cold haemagglutinins
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
Toyota et al. Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies)
JPS60501241A (ja) ウイルス抗原、その製法および診断と治療（ワクチン）におけるその使用
RU2001134499A (ru) Диагностика и лечение атеросклероза и ишемической болезни сердца
Wicher et al. Cell response in rabbits infected with T. pallidum as measured by the leucocyte migration inhibition test.
Namba et al. Effect of serum and serum globulin of patients with myasthenia gravis on neuromuscular transmission
Harris et al. Agglutination by human sera of erythrocytes incubated with streptococcal culture concentrates
Maurer et al. On nonantigenicity of polysaccharides in guinea pigs
Matheson et al. Serologic relationships between β-lysins of different species
Fraser et al. Proteins retained with hyaluronic acid during ultrafiltration of synovial fluid
Lundblad et al. The antigenic nature of heat‐treated human plasma protein fractions
SU1446572A1 (ru) Способ дифференциальной диагностики инсулиннезависимого и инсулинзависимого сахарного диабета
CN1231424A (zh) 用于人畜旋毛虫病快速诊断的试剂及其制备方法
GB916455A (en) Non-toxic antigens and process for producing same
SU637063A1 (ru) Реактив дл определени тироксинсв зывающей способности белков сыворотки крови

Legal Events

Date Code Title Description
8364 No opposition during term of opposition